NCT00618345View on ClinicalTrials.gov

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

August 31, 2008

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

everolimus

GENETIC

DNA analysis

GENETIC

protein analysis

GENETIC

western blotting

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

PROCEDURE

biopsy

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00618345 - Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter